We hereby consent to the incorporation by reference in this Post-Effective Amendment No. 7 to the registration statement on Form N-4 (the “Registration Statement”) of our report dated April 28, 2016 relating to the financial statements of Variable Annuity Account Five, which appears in the Post-Effective Amendment No. 6 to the registration statement on Form N-4 (File No. ​). We also consent to the incorporation by reference in this Registration Statement of our report dated April 28, 2016, relating to the financial statements of American General Life Insurance Company, which appears in the Post-Effective Amendment No. 6 to the registration statement on Form N-4 (File No. ​). We also consent to the reference to us under the heading “Financial Statements” in such Registration Statement.

We hereby consent to the incorporation by reference in this Post-Effective Amendment No. 34 to the Registration Statement on Form N-4 (333-162673) (the “Registration Statement”) of our report dated March 19, 2021 relating to the consolidated financial statements of Pruco Life Insurance Company and its subsidiary and consent to the incorporation by reference in the Registration Statement of our report dated April 5, 2021 relating to the financial statements of each of the subaccounts of Pruco Life Flexible Premium Variable Annuity Account indicated in our report, which appear in the Statement of Additional Information included in the Post-Effective Amendment No. 33 to the Registration Statement on Form N-4 (No. 333-162673) dated April 5, 2021. We also consent to the reference to us under the heading “Experts”, which appears in the Statement of Additional Information included in the Post-Effective Amendment No. 33 to the Registration Statement on Form N-4 (No. 333-162673) dated April 5, 2021, which is incorporated by reference in this Registration Statement.

When the terms of this Certificate of Incorporation refer to a specific agreement or other document or a decision by any body, person or entity to determine the meaning or operation of a provision hereof, the secretary of the Corporation shall maintain a copy of such agreement, document or decision at the principal executive offices of the Corporation and a copy thereof shall be provided free of charge to any stockholder who makes a request therefor. Unless otherwise provided in this Certificate of Incorporation, a reference to any specific agreement or other document shall be deemed a reference to such agreement or document as amended, restated or supplemented from time to time in accordance with the terms of such agreement or document.

We hereby consent to the incorporation by reference in this Post-Effective Amendment No. 12 to the Registration Statement on Form N-4 (No. 333-190294) (the “Registration Statement”) of our report dated March 25, 2019, relating to the consolidated financial statements and financial statement schedules of Protective Life Insurance Company and subsidiaries for the year ended December 31, 2018. We also consent to the reference to us under the heading “Experts” in such Registration Statement.

License and Right of Reference. Effective as of the Closing Date, the Seller, on behalf of itself, each Seller Affiliate and its and their respective transferees, successors and assigns: (a) (i) hereby grants to the Purchaser and its Affiliates, to the extent legally permissible and practicable, a worldwide, exclusive, irrevocable, perpetual, royalty-free, fully paid-up, non-transferable license (except in connection with a permitted assignment of this Agreement or any other Transactional Agreement), with the right to grant sublicenses through multiple tiers, under the Intellectual Property set forth on Part ​ of the Disclosure Schedule (the “Licensed Intellectual Property”) in connection with, and to the extent necessary for, the operation of the Purchaser’s flow cytometry business, including for the manufacture, sale and use of Products by or on behalf of Purchaser or its Affiliates, and # hereby covenants, to the extent legally permissible, not to commence or maintain anywhere in the world any action or proceeding against Purchaser or any of its Affiliates or its or their customers (solely in connection with such customers’ use of the Products as provided by Purchaser and its Affiliates) based upon assertion of infringement of any Intellectual Property or Technology owned by Seller or any Seller Affiliate as of the Closing Date by the operation of the Purchaser’s flow cytometry business, including by the manufacture, use, sale or importation of Products by or on behalf of Purchaser or its Affiliates, in substantially the same manner as conducted by the Seller and the Seller Affiliates as of the Closing Date; and # hereby grants to the Purchaser and its Affiliates, to the extent legally permissible and practicable, a worldwide, non-exclusive, perpetual, irrevocable, royalty-free, fully paid-up and non-transferable (except in connection with a permitted assignment of this Agreement or any other Transactional Agreement) right of reference to all Governmental Authorizations that are necessary for the operation of the Business by the Seller, Controlled by the Seller

We hereby consent to the incorporation by reference in this Registration Statement on Form N-1A of our report dated September 28, 2015, relating to the financial statements and financial highlights which appear in the July 31, 2015 Annual Report to Shareholders of BlackRock Macro Themes Fund (one of the series constituting BlackRock Funds), which is also incorporated by reference into the Registration Statement. We also consent to the references to us under the headings "Financial Highlights", “Financial Statements” and "Independent Registered Public Accounting Firm" in such Registration Statement.

We hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (No. 333-219210) and Form S-8 (Nos. 333-210935 and 333-220988) of Mesoblast Limited of our report dated ​ relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 20-F.

amends or supplements (other than a prospectus supplement relating solely to an offering of securities other than the Placement Shares) the Registration Statement or the Prospectus relating to the Placement Shares by means of a post-effective amendment, sticker, or supplement but not by means of incorporation of documents by reference into the Registration Statement or the Prospectus relating to the Placement Shares;

We consent to the incorporation by reference in the Registrant Statement on Form S-8 and Registration Statement on Form F-3 and related Prospectuses of Biondvax Pharmaceuticals Ltd. of our report dated March 28, 2022 with respect to the financial statements of Biondvax Pharmaceuticals Ltd., included in this Annual Report of 20-F for the year ended December 31, 2021.

Not less than three Trading Days prior to the filing of a Registration Statement or any related Prospectus or any amendment or supplement thereto, furnish to the Holders copies of all such documents proposed to be filed (other than those incorporated by reference). Notwithstanding the foregoing, ​ shall not be required to furnish to the Holders any prospectus supplement being prepared and filed solely to name new or additional selling stockholders unless such Holders are named in such prospectus supplement. In addition, in the event that any Registration Statement is on Form S-1 (or other form which does not permit incorporation by reference), ​ shall not be required to furnish to the Holders any prospectus supplement containing information included in a report or proxy statement filed under the Exchange Act that would be incorporated by reference in such Registration Statement if such Registration Statement were on Form S-3 (or other form which permits incorporation by reference). ​ shall duly consider any comments made by Holders and received by ​ not later than two Trading Days prior to the filing of the Registration Statement, but shall not be required to accept any such comments to which it reasonably objects.